What is TuHURA Biosciences, Inc.'s acquisitions?

TuHURA Biosciences, Inc. (HURA) reported acquisitions of $150.9K in Q2 2025.

What does acquisitions mean?

Cash paid for business acquisitions net of cash acquired in the target company — the primary M&A cash flow line.

Bristol-Myers SquibbBMY

$65M-16.7%

Revenue-—

Net income-$7.5M-13.1%

EPS (diluted)-$0.13+13.3%

Cash & equivalents$6.3M+1.3%

Total debt$456.9K+178%

Total equity$23.2M+135%

Total assets$29.7M+103%

Operating cash flow-$4.4M+6.9%

CapEx$48.8K+14.5%

Free cash flow-$4.5M+6.7%

Market cap$155.39M+45.8%

Enterprise value$149.54M+52.3%

Return on equity-187.2%—

Debt / equity0×0.0×

Current ratio1.2×-1.8×

Reported directly by TuHURA Biosciences, Inc. in its filing.

Tagged under the XBRL concept us-gaap:PaymentsToAcquireBusinessTwoNetOfCashAcquired.

The official record: TuHURA Biosciences, Inc.’s 10-Q, filed August 14, 2025, on SEC EDGAR. View the filing →

Connect your AI assistant and compare it to peers, right in your chat.

What is TuHURA Biosciences, Inc.'s acquisitions?: TuHURA Biosciences, Inc. (HURA) reported acquisitions of $150.9K in Q2 2025.
What does acquisitions mean?: Cash paid for business acquisitions net of cash acquired in the target company — the primary M&A cash flow line.